Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Mirati Therapeutics is at the forefront of precision medicine, with a pipeline full of drugs targeting tumors expressing specific mutations.
The company replaced its CEO and reported strong revenue growth.
The company presented phase 2 data from its non-small cell lung cancer therapy.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.